Clinical benefit of INCB7839, a potent and selective ADAM inhibitor, in combination with trastuzumab in patients with metastatic HER2+ breast cancer.

R. C. Newton, E C Bradley, Richard S. Levy, Dinesh Doval, Shailesh Bondarde, T. P. Sahoo, D. Lokanatha, P.K. Julka, Raj Nagarkar, Steven Friedman

Journal of Clinical Oncology · 2010 · 45 citations · 0 references

Concepts

Abstract

3025 Background: In HER2+ breast cancer, the HER2 protein is cleaved by the metalloproteinase ADAM10 resulting in release of the HER2 extracellular domain (ECD) into the serum while the truncated HER2 receptor (p95) remains in the membrane as a constitutively active kinase. Studies have shown that the presence of p95 is associated with poor clinical outcome, including resistance to trastuzumab-based therapy. Therefore, inhibition of HER2 cleavage by the ADAM inhibitor INCB7839 may enhance the clinical efficacy of trastuzumab in HER2+ breast cancer patients. Methods: This study was initiated as a single arm modified dose escalation open label trial of INCB7839 + trastuzumab in women with HER2+ metastatic breast cancer, naïve to chemotherapy. Three doses of INCB7839 were studied (100 mg, 200 mg, 300 mg BID) with an expansion arm at the 300 mg dose. Trastuzumab was administered on a Q3 week schedule. Pharmacokinetics, plasma HER2 ECD levels and p95 expression in tumor tissue were assessed in addition to clinical response and safety. The study has been further expanded to evaluate the addition of docetaxel to INCB7839 + trastuzumab. Results: To date, 51 HER2+ patients have been enrolled in the study. INCB7839 administration results in a dose-dependent reduction in plasma HER2 ECD. With the INCB7839 + trastuzumab combination, the currentoverall response rate is 50% (13/26 evaluable patients) with a higher response rate (9/14 or 64%) observed in patients with INCB7839 plasma concentrations above the IC50 for HER2 cleavage. Importantly, INCB7839 increases the clinical response rate and time to progression in p95+ patients, with equivalent responses observed in the p95+ and p95− patients. Thirteen patients have initiated addition of docetaxel and the combination of the three agents has been generally safe and well tolerated. Conclusions: Biomarker and clinical data from this trial demonstrate that INCB7839 can markedly reduce HER2 cleavage in patients with HER2+ breast cancer, and suggest that INCB7839 can improve the response to trastuzumab and render a subpopulation of HER2+ patients, who are p95+ and are predicted to be trastuzumab resistant, responsive to trastuzumab therapy. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Incyte Incyte